The Life Science business of Merck KGaA, Darmstadt, Germany Becomes a Trusted Partner of the Flemingsberg Science Foundation

Flemingsberg, 2025-06-23

The Life Science business of Merck KGaA, Darmstadt, Germany, and Flemingsberg Science Foundation collaborate to promote Life Science sector in Flemingsberg. This strategic partnership aims to strengthen development of ATMP (Advanced Therapy Medicinal Products).

Given the rapid development of ATMP (Advanced Therapy Medicinal Products) in Flemingsberg, the foundation seeks to create a strong support network for individuals and companies within the Life Science sector. Through this partnership with the Life Science business of Merck KGaA, Darmstadt, Germany, Flemingsberg Science Foundation is taking another significant step towards building a robust infrastructure for innovation and growth in the region.

“Together with the foundation and other partners, we will contribute by identifying growth opportunities, infrastructure needs, and investment areas that can further develop the ATMP environment in Flemingsberg. Through our presence in Flemingsberg, we can efficiently and effectively meet the specific needs of companies and organizations within the ATMP sector.” – Gianluca Tagliapietra, Senior VP Commercial SLS EMEA, the Life Science business of Merck KGaA, Darmstadt, Germany.

“The Life Science business of Merck KGaA, Darmstadt, Germany provides cutting-edge technology, expertise, and strategic partnerships that strengthen the life science cluster in Flemingsberg in multiple ways, both directly and in the long term. Their presence creates opportunities for our companies and organizations to benefit from their expertise and enables collaborations through meetings and events. Together with our other trusted partners, they also contribute the knowledge and network we need to continue developing Flemingsberg, as well as the platform ATMP Flemingsberg”. – Johnny Högberg, CEO of the Flemingsberg Science Foundation.

As a trusted partner, the Life Science business of Merck KGaA, Darmstadt, Germany, will, among other things, organize at least three events per year, become a member of Novum Labs – an innovative environment with state-of-the-art laboratory facilities and room for growth – and host workshops, seminars, and panel discussions on regulatory challenges, commercialization, and scientific advancements.

This partnership is part of the initiative to strengthen the growth and establishment of small and medium-sized enterprises (SMEs) in the life science sector in the Stockholm region.

Johnny Högberg
CEO, stiftelsen Flemingsberg Science
johnny.hogberg@flemingsbergscience.se
070 550 12 73

BioLamina Establishes Operations in Flemingsberg – A Key Player in ATMP Development

As the world’s first and only producer of laminins, the biotechnology company BioLamina has expanded its operations and chosen to establish part of its business in Flemingsberg. Using laminins, a protein that creates an optimal environment for cells to expand and/or differentiate, they are a key player in the development of ATMPs (Advanced Therapy Medicinal Products) in Sweden and globally.

BIO-Europe – A Conference for Future Medical Innovations

BIO-Europe is Europe’s largest partnering conference for the biotechnology, pharmaceutical, and life science industries. The conference serves as a meeting place where companies, researchers, investors, and other stakeholders in the industry can network, establish collaborations, and discuss business opportunities. The event is held annually in various European cities. This year, BIO-Europe took place in Stockholm from November 4th to 6th, where discussions included advanced cell and gene therapies as the medicine of the future.

Go to Top